Dysmobility syndrome: a paradigm shift in fracture prevention

Neil Binkley, Diane Krueger

Abstract


Fragility fractures engender major healthcare cost, reduce independence/quality and life and increase mortality risk. Despite availability of multiple therapies to reduce risk for future fracture, few patients are treated even following hip fracture. Clearly, approaches of the past aimed at reducing fragility fracture risk, primarily by diagnosing osteoporosis and initiating bone-active medications, have failed.  A different approach is required; such a change in focus is proposed here.  Briefly, the dysmobility syndrome concept recognizes fragility fracture as the clinical outcome of consequence and appreciates that osteoporosis is only part of the syndrome leading to “osteoporosis-related” fracture. Other components of this syndrome include sarcopenia, obesity, diabetes, osteoarthritis, and potentially multiple other factors that increase risk for falls with attendant increased fracture risk.  In summary, the dysmobility syndrome concept moves the field, and also, importantly, older adults at risk for fragility fracture, beyond a singular focus on bone to more appropriately focus on a holistic approach to fracture risk reduction.


Keywords


fracture; osteoporosis; sarcopenia; dysmobility syndrome; falls

Full Text:

PDF

References


Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis Medication Use after Hip Fracture in U.S. Patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929-37. doi: 10.1002/jbmr.2202.

Kim SC, Kim DH, Mogun H. Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. J Bone Miner Res. 2016;31(8):1536-40. doi: 10.1002/jbmr.2832.

Khosla S, Shane E. A Crisis in the Treatment of Osteoporosis. J Bone Miner Res. 2016;31(8):1485-7.doi: 10.1002/jbmr.2888.

Akesson K, Marsh D, Mitchell PJ, et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013;24(8):2135-52. doi: 10.1007/s00198-013-2348-z.

Eisman JA, Bogoch ER, Dell R, Harrington JT, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012;27(10):2039-46. doi: 10.1002/jbmr.1698.

Miller AN, Lake AF, Emory CL. Establishing a fracture liaison service: an orthopaedic approach. J Bone Joint Surg. 2015;97(8):675-81. doi: 10.2106/JBJS.N.00957.

Dell R, Greene D, Schelkun SR, Williams K. Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surg. 2008;90(suppl 4):188-194. doi: 10.2106/JBJS.H.00628.

Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439-43. doi: 10.1007/s00198-014-2655-z.

Siris ES, Boonen S, Mitchell PJ, Bilezikian J, Silverman S. What's in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int, 2012;23(8):2093-7. doi: 10.1007/s00198-012-1991-0.

Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone. 2004;34:195-202. PMID: 14751578.

Anonymous, Consensus Development Conference: Prophylaxis and Treatment of Osteoporosis. Am J Med. 1990;90:107-10. PMID: 1986575

Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41. PMID: 8950879.

Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. doi: 10.1056/NEJMoa067312.

McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-40. doi: 10.1056/NEJM200102013440503.

Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-809. doi: 10.1056/NEJMoa074941.

Neer RM1, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41. doi: 10.1056/NEJM200105103441904.

Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One. 2009;4(9):e7038. doi: 10.1371/journal.pone.0007038.

Parkkari J, Kannus P, Palvanen M, et al. Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: a prospective controlled hip fracture study with 206 consecutive patients. Calcif Tissue Int. 1999;65(3):183-7. PMID: 10441647.

Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348(9021):145-9. PMID: 8684153.

Nguyen DN, Pongchaiyakul C, Center JR, et al. Identification of high-risk individuals for hip fracture: A 14-year prospective study. J Bone Miner Res. 2005;20(11):1921-8. doi: 10.1359/JBMR.050520.

Cawthon PM, Fullman RL, Marshall L, et al. Physical performance and risk of hip fractures in older men. J Bone Miner Res. 2008;23(7):1037-44. doi: 10.1359/jbmr.080227.

Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249-56. doi: 10.1016/j.jamda.2011.01.003.

Looker AC, Wang CY. Prevalence of reduced muscle strength in older U.S. adults: United States, 2011-2012. NCHS Data Brief. 2015;179:1-8. PMID: 25633238.

Morley JE, Malmstrom TK, Frailty, sarcopenia, and hormones. Endocrinol Metab Clin North Am. 2013;42(2):391-405. doi: 10.1016/j.ecl.2013.02.006.

Binkley N, Buehring B. Beyond FRAX: it's time to consider "sarco-osteopenia". J Clin Densitom. 2009;12(4):413-6. doi: 10.1016/j.jocd.2009.06.004.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. doi: 10.1093/ageing/afq034.

Studenski SA, Peters KW, Alley DE, et al. The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547-58. doi: 10.1093/gerona/glu010.

Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: A Critical appraisal of the current evidence. Clin Nutr. 2012;31(5):583-601. doi: 10.1016/j.clnu.2012.06.010.

Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767-73. doi: 10.1056/NEJM199503233321202.

Roy DK, O'Neill TW, Finn JD, et al. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int. 2003;14(1):19-26. doi: 10.1007/s00198-002-1317-8.

Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone. Nat Clin Pract Rheumatol. 2006;2(1):35-43. doi: 10.1038/ncprheum0070.

Rosen CJ, Klibanski A. Bone, fat and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009;122:409-414. doi: 10.1016/j.amjmed.2008.11.027.

Addison O, Robin L. Marcus RL, LaStayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. Int J Endocrinol. 2014;2014:309570. doi:10.1155/2014/309570.

Compston JE, Watts NB, Chapurlat R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011;124:1043-50. doi: 10.1016/j.amjmed.2011.06.013.

Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4):399-428. doi: 10.1007/s00198-008-0560-z.

Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431-44. doi: 10.1007/s00198-008-0588-0.

Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014;29(3):518-30. doi: 10.1002/jbmr.2176.

McCloskey EV, Odén A, Harvey NC, et al. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int. 2015;96(6):500-9. doi: 10.1007/s00223-015-9980-x.

Binkley N, Krueger D, Buehring B. What's in a name revisited: should osteoporosis and sarcopenia be considered components of "dysmobility syndrome?". Osteoporos Int. 2013;24(12):2955-9. doi: 10.1007/s00198-013-2427-1.

Schwartz AV. Epidemiology of fractures in type 2 diabetes. Bone. 2016;82:2-8. doi: 10.1016/j.bone.2015.05.032.

Wang J, You W, Jing Z, Wang R, Fu Z, Wang Y. Increased risk of vertebral fracture in patients with diabetes: a meta-analysis of cohort studies. Int Orthop. 2016;40(6):1299-307. doi: 10.1007/s00264-016-3146-y.

Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27(2):301-8. doi: 10.1002/jbmr.556.

Prieto-Alhambra D, Nogues X, Javaid MJ, et al. An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis. 2013;72(6):911-7. doi: 10.1136/annrheumdis-2012-201451.

Zasadzka E, Borowicz AM, Roszak M, Pawlaczyk M. Assessment of the risk of falling with the use of timed up and go test in the elderly with lower extremity osteoarthritis. Clin Interv Aging. 2015;10:1289-98. doi: 10.2147/CIA.S86001.

Ebly EM, Hogan DB, Fung TS. Potential adverse outcomes of psychotropic and narcotic drug use in Canadian seniors. J Clin Epidemiol. 1997;50(7):857-63. PMID: 9253399.

Rolita L, Spegman A, Tang X, Cronstein BN. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Geriatr Soc. 2013;61(3):335-40. doi: 10.1111/jgs.12148.

Bolland MJ, Siu AT, Mason BH, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res. 2011;26:420-7. doi: 10.1002/jbmr.215.

Clynes MA, Edwards MH, Buehring B, Dennison EM, Binkley N, Cooper C.Definitions of Sarcopenia: Associations with Previous Falls and Fracture in a Population Sample. Calcif Tissue Int. 2015;97(5):445-52. doi: 10.1007/s00223-015-0044-z.

Buehring B, Lewis B, Hansen K, et al. Association of Musculoskeletal Health Score with Fracture Risk in the MrOS cohort. J Bone Miner Res. 2016;31(Suppl 1). Available from: http://www.asbmr.org/education/AbstractDetail?aid=104ce55b-45f8-4bcb-9b01-402428abafe4.

Looker AC. Dysmobility syndrome and mortality risk in US men and women age 50 years and older. Osteoporos Int. 2015;26(1):93–102. doi: 10.1007/s00198-014-2904-1.

Buehring B, Binkley N. Myostatin--the holy grail for muscle, bone, and fat? Curr Osteoporos Rep. 2013;11(4):407-14. doi: 10.1007/s11914-013-0160-5.

Osler W. Sir William Osler. Aphorisms, ed. W.B. Bean. 1961, Springfield IL: C. C. Thomas, Oxford, Blackwell Scientific Publs.




DOI: https://doi.org/10.22141/2224-1507.7.1.2017.102430

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru